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Abstract: Arterial remodeling refers to the structural and functional changes of the vessel wall
that occur in response to disease, injury, or aging. Vascular smooth muscle cells (VSMC) play a
pivotal role in regulating the remodeling processes of the vessel wall. Phenotypic switching of
VSMC involves oxidative stress-induced extracellular vesicle release, driving calcification processes.
The VSMC phenotype is relevant to plaque initiation, development and stability, whereas, in the
media, the VSMC phenotype is important in maintaining tissue elasticity, wall stress homeostasis and
vessel stiffness. Clinically, assessment of arterial remodeling is a challenge; particularly distinguishing
intimal and medial involvement, and their contributions to vessel wall remodeling. The limitations
pertain to imaging resolution and sensitivity, so methodological development is focused on improving
those. Moreover, the integration of data across the microscopic (i.e., cell-tissue) and macroscopic
(i.e., vessel-system) scale for correct interpretation is innately challenging, because of the multiple
biophysical and biochemical factors involved. In the present review, we describe the arterial
remodeling processes that govern arterial stiffening, atherosclerosis and calcification, with a particular
focus on VSMC phenotypic switching. Additionally, we review clinically applicable methodologies
to assess arterial remodeling and the latest developments in these, seeking to unravel the ubiquitous
corroborator of vascular pathology that calcification appears to be.
Keywords: arterial remodeling; vascular smooth muscle cell; vascular calcification; vascular stiffness;
hypertension; phenotype switching
1. Introduction
The vessel wall consists of multiple cells, including endothelial cells (ECs), vascular smooth muscle
cells (VSMCs), fibroblasts and pericytes, and structural extracellular matrix (ECM) components, such as
elastin and collagen [1]. ECs form the innermost layer, being the barrier between the blood-carrying
lumen and vessel wall. In the vessel wall, ECs are surrounded by the tunica media, consisting
almost entirely of circumferentially oriented VSMCs. Medial VSMCs, facilitating vessel dilation and
constriction, are surrounded by interconnected elastic lamellae [2]. The outer layer of the vessel wall
is the adventitia and contains ECM, maintaining structural integrity under peak mechanical load,
and fibroblasts and progenitor (mesenchymal stem cell-like, MSC-like) cells. The interplay of all
components of the vessel wall is needed to preserve vascular health [3–5].
The vessel wall is continuously exposed to biomechanical and biochemical stressors that elicit
functional and adaptative responses. For instance, when blood flow is acutely increased, the increased
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wall shear stress (or friction) is sensed by ECs, which release relaxants. These relaxants (e.g., nitric oxide,
NO) lower the active tone of VSMCs, leading to (flow-mediated) vessel dilation to counteract the initial
increase in wall shear stress [6]. Long-term changes in wall shear stress provoke diameter adaptation [7].
Wall thickness changes are seen in response to increased wall stress (or wall tension), due to high blood
pressure [8]. Such arterial remodeling responses shape early development of the macro-circulation,
but are also affected by normal aging processes [9]. A multitude of biological processes contribute
to pathological vascular remodeling, such as inflammation, oxidative stress, lipid accumulation,
and degradation of the ECM [10,11]. Due to the heterogeneity of vascular remodeling, it is difficult to
pin-point single biological processes responsible for vascular disease. Lessons from genetic disorders
such as pseudoxanthoma elasticum (PXE), Marfan’s syndrome and Keutel syndrome, have addressed
the complexity of arterial remodeling [12]. A better understanding of the complexity of arterial
remodeling will help unravel its role as a cause or consequence of cardiovascular disease (CVD).
VSMCs in the medial layer of the vessel wall play a key role in arterial remodeling. VSMCs are
the most abundant cell type in the arterial vessel wall and are pivotal in maintaining vessel structure
and function [13]. VSMCs are considered heterogeneous and display a high degree of plasticity [5].
Under physiological conditions, VSMCs have a contractile phenotype which facilitates the contraction
and dilation of the vasculature, which, in smaller resistance arteries, is key to the regulation of blood
flow. Upon biological stress signals or vascular injury, VSMCs respond by losing contractility markers
and differentiate towards a synthetic VSMC phenotype. Synthetic VSMCs subsequently express
proteins involved in proliferation and migration [14]. Contractile VSMCs may adapt to stress by
differentiating towards synthetic VSMCs which are able to newly synthesize ECM components such
as collagen. To remodel the ECM, synthetic VSMCs produce metalloproteinases (MMPs), such as
collagenases and elastases, that allow them to migrate to sites of injury [15–17]. VSMC-mediated
remodeling of ECM within the vessel wall may result in increased arterial stiffness [13,18], contributing
to systolic hypertension and altered hemodynamic conditions in end-organs such as the brain, kidneys
and heart [19].
VSMCs are involved in many vascular diseases, such as atherosclerosis and aneurysm formation.
In all these vascular pathologies, vascular calcification is involved [5,20,21]. Vascular calcification is
defined as the deposition of calcium crystals within the vessel wall, initiated as microcalcification
and propagating towards macrocalcifications [22], and, eventually, encroaching entire segments of
the vasculature [23]. Vascular calcification is an active process with a key role for VSMCs, including
apoptosis [24], osteochondrogenic transdifferentiation [25], extracellular vesicle release [2], calcium
overload [26], and cellular senescence [27] (Figure 1). The aim of the present review is to provide an
overview of the pathways underlying arterial remodeling, with a particular focus on the role of VSMCs
and calcification-related processes.
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Figure 1. (a) Vascular smooth muscle cell (VMSC) phenotypic switching. Under physiological 
conditions, VSMCs display a contractile phenotype that regulates vessel structure and function. 
Under stress, arterial remodeling will occur, leading to VSMC phenotypic switching. Factors inducing 
the synthetic phenotype include platelet derived growth factors (PDGF), protease-activated receptors 
(PARs) and tumor necrosis factor-alpha (TNF-α). Synthetic VSMCs initiate vessel repair and can 
switch back to the contractile phenotype, driven by factors such as heparin or laminin. The osteogenic 
phenotype can be induced by prolonged exposure to BMP-2 or high phosphate. Osteogenic VSMCs 
shed extracellular vesicles that promote vascular calcification. Panel (b). Pathways affecting vascular 
calcification. Vascular calcification is an active process which can be initiated by several pathways, 
including: 1. biochemical factors, 2. physical factors, 3. vascular calcification (VC) inhibitors and 4. 
ECM factors. Biochemical factors, such as raised calcium and phosphate levels and PDGF, are stress 
molecules that induce VSMCs to switch towards a synthetic or osteogenic phenotype, including an 
increased release of extracellular vesicles. The ECM of the vessel wall directly influences VSMCs. 
Changes in collagen and elastin content cause VSMCs to change morphology and phenotype. VSMCs 
in turn, produce MMPs that induce structural changes in the vessel wall by rearranging collagen and 
elastin, promoting the migration and proliferation of VSMCs and other cell types. Physical factors 
such as shear stress and tensile stress affect ECs’ NO release, which influences the VSMC phenotype. 
Shear-induced stress induces a synthetic phenotype by decreasing a-SMA, MYH and smtn expression. 
Tensile stretch induces VSMCs to produce ECM proteins, such as collagen and fibronectin promoting 
vessel fibrosis. VC inhibitors, such as OPN, MGP and PP1, affect the VSMC phenotype by inducing 
changes in RNA expression patterns. Taken together, all stimuli play a part in an orchestrated VSMC 
response, ultimately promoting vascular calcification. 
2. Biology of Vascular Remodeling 
2.1. Arterial Remodeling 
Arterial remodeling reflects the adaptation of the vessel wall to biochemical and biomechanical 
stimuli [9,12]. In the vasculature, two types of remodeling can be distinguished: outward and inward 
remodeling, with respective hypertrophy (thickening) or hypotrophy (thinning) of the vessel wall. 
Large conduit vessels do not have the ability to constrict in response to stress, and therefore show 
hypertrophic remodeling. Atherosclerosis is characterized by an increase in vessel diameter, with the 
thickening of both the media and intima, and classically termed outward hypertrophic remodeling 
[28]. Aneurysm formation is characterized by an increase in vessel diameter, with a thinning of the 
Figure 1. (a) Vascular smooth muscle cell (VMSC) phenotypic switching. Under physiological
conditions, VSMCs display a contractile phenotype that regulates vessel structure and function. Under
stress, arterial remodeling will occur, leading to VSMC phenotypic switching. Factors inducing the
synthetic phenotype include platelet derived growth factors (PDGF), protease-activated receptors
(PARs) and tumor necrosis factor-alpha (TNF-α). Synthetic VSMCs initiate vessel repair and can
switch back to the contractile phenotype, driven by factors such as heparin or laminin. The osteogenic
phenotype can be induced by prolonged exposure to BMP-2 or high phosphate. Osteogenic VSMCs
shed extracellular vesicles that promote vascular calcification. Panel (b). Pathways affecting vascular
calcification. Vascular calcification is an active process which can be initiated by several pathways,
including: 1. biochemical factors, 2. physical factors, 3. vascular calcification (VC) inhibitors and 4.
ECM factors. Biochemical factors, such as raised calcium and phosphate levels and PDGF, are stress
molecules that induce VSMCs to switch towards a synthetic or osteogenic phenotype, including an
increased release of extracellular vesicles. The ECM of the vessel wall directly influences VSMCs.
Changes in collagen and elastin content cause VSMCs to change morphology and phenotype. VSMCs
in turn, produce MMPs that induce structural changes in the vessel wall by rearranging collagen and
elastin, promoting the migration and proliferation of VSMCs and other cell types. Physical factors
such as shear stress and tensile stress affect ECs’ NO release, which influences the VSMC phenotype.
Shear-induced stress induces a synthetic phenotype by decreasing a-SMA, MYH and smtn expression.
Tensile stretch induces VSMCs to produce EC proteins, such as collagen and fibronectin promoting
vessel fibrosis. VC inhibitors, such as OP , P and PP1, affect the VSMC phenotype by inducing
changes in RNA expression patterns. a e t et er, all sti uli play a part in an orchestrated VSMC
response, ultimately promoting vascular calcific ti .
2. Biology of Vascular Remodeling
2.1. Arterial Remodeling
Arterial remodeling reflects the adaptation of the vessel wall to biochemical and biomechanical
stimuli [9,12]. In the vasculature, two types of remodeling can be distinguished: outward and
inward remodeling, with respective hypertrophy (thickening) or hypotrophy (thinning) of the vessel
wall. Large conduit vessels do not have the ability to constrict in response to stress, and therefore
show hypertrophic remodeling. Atherosclerosis is characterized by an increase in v ssel diameter,
wi th thickening of both the med a nd intima, and classically termed outward hypertrophic
remodeli g [28]. Aneurysm formation is characterized by an increas in vessel diameter, with a
thinning of the vessel wall, and termed outward hypothropic remodeling [29] (Figure 2). Inward
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remodeling is less frequently seen and is observed in more muscular peripheral arteries, probably
reflecting the sustained vasoconstriction of vessels [30].
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Figure 2. Vascular remodeling types. re are several types of arterial remodeling: hypotrophic,
eutrophic and hypertrophic. iti ll , re odeling can be inward and outward. Hypotrophic
remodeling res lts i a t i er essel all, which can be both inward and outward. In both cases,
the wall-to-lumen ratio decreases. Hypertrophic remodeling results in the thickening of the vessel
wall, that can also be inward and outward. The thickening of the vessel wall results in an increased
wall-to-lumen ratio. In the eutrophic situation, wall-to-lumen ratios do not differ, but the size of the
vessel can change. Atherosclerosis is characterized by an increased wall-to-lumen ratio, with both
thickening of the media and intima and, therefore, is classified as inward or outward hypertrophic
remodeling. Aneurysm formation is characterized by an increase in vessel diameter with a thinning of
the vessel wall (outward hypotrophic remodeling). Inward remodeling is less frequent and is more
associated with muscular peripheral arteries, reflecting sustained vasoconstriction of vessels.
Under low laminar flow, platelet derived growth factors (PDGF) and transforming growth factor-β
(TGF-β) promote inward remodeling by increasing VSMC proliferation and collagen deposition [31].
Inward remodeling also contributes to atherosclerosis, but does not lead to an increased vessel size
(Figure 2). Atherosclerosis development involves many cellular processes, like the recruitment of
inflammatory cells by chemotaxis and infiltration [32].
VSMCs are connected to a fenestrated network of elastin and collagen fibers. The capacity of the
vessel wall to elastically distend is important to accommodate the volume ejected with each heartbeat
and to limit peripheral pressure pulsations. The active tone and spatial arrangement of VSMCs may
influence the mechanical load on the ECM components and, therefore, modulate vessel diameter and
stiffness [18]. Chronic exposure to high blood pressure increases tensile stress [9] to which VSMCs
respond by proliferation, resulting in hyperplasia and thickening of the vascular wall. Concomitant
activity of MMPs facilitates the structural breakdown of elastin ECM, and synthetic VSMCs produce
collagen ECM, attempting to preserve stiffness homeostasis [33]. High blood pressure thus aggravates
age-related stiffening of arteries [34–36]. Additional ECM disturbances, such as the presence of calcium
crystals, have a further impact on the stiffening of the medial layer [37,38].
During aging, it is generally accepted that the number of cells in the vasculature decreases,
although the causes of this finding remain to be established [34]. It has been hypothesized that VSMCs
become senescent and that cell division rates decrease [39]. The recent literature ignores vessel wall
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cellularity and often refers to cellular processes, such as apoptosis, inflammation, calcification and
epigenetic effects, all playing a part in vessel wall aging [20]. Additionally, with aging, collagen content
in major arterial vasculature increases, whereas elastin content decreases and the number of VSMCs
declines [40]. As a consequence, remaining VSMCs are embedded in a collagen-enriched ECM with
fewer cellular focal adhesions [41–43]. Within arterial vessels, differences exist in the content of elastin
to VSMC ratios [44]. Large arteries close to the heart contain more elastin and are therefore called
“elastic” arteries. It is particularly elastic arteries that stiffen with age [45]. Large artery stiffening
results in decreased arterial compliance, especially in those aged over 60 years [19,46,47]. Peripheral
vessels contain more VSMCs relative to elastin and are termed “muscular” arteries. In muscular
arteries, the relative elastin content increases with age, most likely caused by the decline in the number
of VSMCs and decreased collagen content [44]. It should be noted that the absolute amount of ECM
proteins in the vasculature decreases with age, but that fat and extracellular material, such as calcium
crystals, increase [48]. Taken together, the number of VSMCs within the vasculature strongly correlates
with vascular stiffening and the arterial remodeling processes [34].
Endothelial function plays an important role in arterial remodeling. Blood flow and normal
wall shear stress stimulate ECs to produce NO (Figure 3). NO induces the relaxation of local VSMCs,
which leads to dilation of the vessel wall. Endothelium-dependent vasodilation decreases with age,
which appears to be associated (perhaps causally or bi-directionally) with a quiescent state of VSMCs
and is clearly implicated to be associated with hypertension and CVD [49,50]. Under pathological
conditions, ECs are known to produce cytokines and growth factors [51], which induces VSMCs
phenotype switching from contractile to a more synthetic phenotype. An increased wall shear stress
increases endothelial derived NO release, further decreasing VSMC proliferation and increasing VSMC
apoptosis [52], resulting in outward remodeling and stiffened vasculature, due to the formation of the
ECM matrix by remaining synthetic VSMCs [34,53].
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hyperpolarization (EDH). EDH has two major pathways: 1. Diffusion of nitric oxide (NO), which is 
produced by ECs and diffuses through the internal elastic lamina (IEL) to induce the relaxation of 
VSMCs. 2. Signaling through myoendothelial gap junctions (MEGJ) that connect ECs directly to 
VSMCs and cross the IEL. This direct communication between ECs and VSMC via MEGJ occurs via 
so-called endothelial derived hyperpolarizing factors (EDHF). 3. Major factors that stimulate EC NO 
secretion are flow or shear-stress alterations. Differences in wall shear rates are known to induce 
endothelial-derived changes in VSMC phenotype. 
Figure 3. Endothelial cell–smooth muscle cell communication. Endothelial cells (ECs) communicate
with vascular smooth muscle cells (VSMCs) in two ways, called endothelial derived hyperpolarization
(EDH). EDH has tw major pathways: 1. Diffusion of ni ric oxide (NO), which is produced by ECs
and diffuses thr ugh the internal elastic lamina (IEL) to induce the relaxation of VSMCs. 2. Signaling
through myoendothelial gap junctions (MEGJ) that connect ECs directly to VSMCs and cross the
IEL. This direct communication between ECs and VSMC via MEGJ occurs via so- alled endothelial
derived hype polarizing factors (EDHF). 3. Major factors that stimulate EC NO secretion are flow
or shear-stress alterations. Differ nces in wall shear rates are known to induce endothelial-derived
changes in VSMC phenotype.
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2.1.1. Inflammation and Arterial Remodeling
Inflammatory processes play a significant role in arterial remodeling and are linked to the
development of atherosclerosis. Chronic low-grade inflammation is a key driver of arterial aging.
VSMC phenotypic switching and ECM biochemical changes activate inflammatory pathways and
oxidative stress signaling [54]. Cytokines determine processes such as endothelial dysfunction, renin
angiotensin activation and metalloproteinases release [55,56]. VSMCs are involved in local vessel wall
inflammatory functions.
Proliferation
VSMCs have low turnover rates in healthy vessels, but increase proliferation upon vascular injury
to initiate repair [57]. Increased expression of aging genes p16INK4a and p21 [58] have been linked to
VSMC senescence and are present in atherosclerotic plaques, indicating lower proliferation and, thus,
decreased repair capacity [59].
Cell Death
Cell death is linked to vascular disease, but absolute rates are difficult to determine. VSMC
apoptosis in atherosclerosis has been linked to plaque vulnerability features [60], and chronic VSMC
apoptosis has been shown to promote atherogenesis and plaque progression [61]. In vascular aging
and medial remodeling, VSMCs cell death does not cause significant inflammation, due to the efficient
IL-1β-mediated clearance of apoptotic bodies by VSMCs [62].
Platelets and Extracellular Vesicles (EVs)
Platelets have shown to affect VSMC inflammatory phenotypes and injury responses [63].
Additionally, platelet EVs induce an inflammatory response in VSMC in vitro [64]. Platelet factor 4
(PF4) has a central role in the stimulation of VSMC-mediated cytokine release, which is primarily
affected by increased krüppel-like factor 4 (KLF-4) transcription. Experimental atherosclerosis models
indicated that PF4 is proatherogenic and it has been found to penetrate deep into the vessel wall,
underlining the importance of platelets aside from their effect on the endothelium [65].
2.2. The Role of VSMC Plasticity in Vascular Remodeling
Under physiological conditions, VSMCs display a contractile phenotype, in which markers such
as alpha-smooth muscle actin (α-SMA), smooth muscle 22-alpha (SM22-α), smoothelin A/B (smtn),
smooth muscle-myosin heavy chain (MYC11) and Calponin-1 (CNN-1) are highly expressed [14,66,67]
(Table 1). VSMCs are heterogeneous with regard to their expression, are derived from different
embryonic origins and have a strong genetic component causing VSMC diversity. Numerous in vivo
studies have shown the existence of diverse VSMC populations within the same artery in rats [68],
pigs [69] and humans [70]. We refer to VSMC plasticity here as the capability of VSMCs to switch
phenotype. VSMC phenotypes are changed by environmental cues, such as soluble biochemical
compounds, ECM proteins and biophysical conditions [33,71] (Figure 1). VSMCs exhibit a whole
array of phenotypes, ranging from contractile–quiescent to migratory–proliferative–synthetic and
osteogenic-, macrophage- or MSC-like [72–74] (Table 1). In the following subsections, we will briefly
describe the most relevant factors that affect VSMC phenotype (Figure 1 and Table 2).
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Table 1. Proteins that define VSMC phenotype.
Protein Gene Name Abbreviation
Expression
Contractile Synthetic
Alpha smooth muscle actin ACTA-2 α-SMA + +
Smooth muscle myosin heavy chain MYH11 SMMHC + −
Smooth muscle 22 alpha TAGLN SM22-α + −
Smoothelin SMTN Smtn + −
Calponin CNN-1 CNN-1 + −
Tumor necrosis factor alpha TNFA TNF-α +
S100 calcium binding protein A4 S100A4 S100A4 − +
Monocyte chemoattractant protein 1 CCL2 MCP-1 − +
+, positive effect; −, negative effect.
Table 2. Factors involved in VSMC phenotype switching.
Factors Involved in VSMC Phenotype Switching Phenotype





Angiotensin II + +
Extracellular matrix components
Integrin: α1β1, α7β1, α8β1 + −
Integrin: α2β1, α5β1, αvβ3 − +
Collagen type I − +






Tensile stress − +




Abbreviations: PDGF, platelet derived growth factor; TGF-β, transforming growth factor beta; PARs
Protease-activated receptors; TNF-α, tumor necrosis factor alpha; KLF4, krüppel-like factor 4; Oct4, octamer-binding
transcription factor 4. +, positive effect; −, negative effect.
2.2.1. Biochemical Compounds
PDGF is an important signaling molecule in the initial phase of VSMC differentiation. During
vascular development, PDGF causes mesenchymal cell recruitment and subsequent proliferation [75].
PDGF is known to induce VSMC differentiation towards a synthetic phenotype, as it downregulates
the contractile marker αSMA in aortic VSMCs [76]. Additionally, PDGF increases proliferation
and migration in pig and human coronary VSMCs [69,77,78]. Moreover, in vivo studies showed
that inhibition of PDGF results in reduced VSMC proliferation and migration after arterial balloon
injury [79,80].
TGF-β, as opposed to PDGF, induces a contractile and non-proliferative VSMC phenotype.
An absence of TGF-β results in severe congenital cardiovascular disease, mainly shown in structural
defects in experimental animals [81]. In vitro treatment of VSMCs with TGF-β induces expression of
αSMA, MHC and CNN1 [69,82,83].
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Activated coagulation proteins also have been shown to affect VSMC phenotype via protease
activated receptors (PARs) [84]. Both tumor necrosis factor-alpha (TNF-α) and angiotensin II have been
shown to induce the contractile, as well as the synthetic, phenotype of VSMCs. It has been shown that
angiotensin II affects VSMC phenotypic plasticity via the induction of ROS and decreased scavenging
activity of nitrate reductase (NAD(P)H) oxidases [85] and subsequently induces aneurysm formation
via oxidative stress [21,86].
2.2.2. Extracellular Components
The ECM in which VSMCs are embedded also affects VSMC phenotype. VSMC phenotype is
modulated via integrin receptors that are present on ECM proteins [87]. ECM consists of structural
proteins, such as collagen, elastin and proteoglycans. For instance, the proteoglycan heparin promotes
VSMC contractility. In vitro, heparin treatment of VSMCs induces a contractile phenotype and slows
down its proliferation [69,88]. Collagen has pleiotropic effects on VSMC phenotype, depending on
the type of collagen. Collagen type-I and fibronectin induce a synthetic VSMC phenotype [89,90]
with proliferation [91,92]. On the contrary, collagen type-IV and laminin promote a contractile VSMC
phenotype [89,93]. Intact elastin is associated with a contractile VSMC phenotype. The loss of elastin,
by a genetic mutation, is associated with increased hypertrophy and hyperplasia of VSMCs [94,95].
Additionally, elastin remodeling, by the modulation of cathepsins and MMPs, promotes VSMC
phenotypic switching that induces calcification [96,97].
Not only composition, but also the organization of structural fibers, determines VSMC phenotype.
Culturing VSMCs in 3D compared to 2D increases contractile expression markers and induces
TGF-β expression [98,99]. Culturing VSMCs on scaffold templates controls spatial organization and
morphological response of VSMCs, indicating that VSMCs react to structural environmental changes
to retain vessel function [100].
2.2.3. Biophysical Factors
Hemodynamics at the vessel level (flow and transmural pressure) also affect VSMCs by determining
tensile loading and active tone (e.g., by NO). Changes in vessel wall shear stress modulate EC NO
release, and influence VSMCs via cell–cell interaction with ECs [101]. Using co-cultures of ECs and
VSMCs, shear stress induces a synthetic VSMC phenotype by decreasing α-SMA, MYH and smtn
expression [69]. However, 2D co-culture systems do not mimic the complex vessel wall architecture
in vivo. Changes in blood pressure directly transfer into changes in ECM tensile stress, which,
as determined by (local) matrix elastic behavior and VSMC stiffness, results in VSMC deformation
(i.e., mechanical strain). Alterations in VSMC strain are understood to modulate cellular phenotype [33].
Mechanical stretching forces applied directly to VSMCs enhance the expression of ECM proteins, such
as collagen and fibronectin [102]. Biophysical factors in the physiological range promote VSMCs to
maintain or adopt a contractile phenotype, whereas pathological biophysical stimuli promotes VSMCs
to switch towards a synthetic phenotype.
2.2.4. Transcriptional Regulators
KLF4 is an important transcriptional regulator defining VSMC phenotype during
development [103] and after vascular injury [104]. KLF4 expression is increased in lesions of ApoE-/-
mice on a Western type diet [105]. Additionally, there is increased binding of KLF4 to αSMA and
SM22α promotors upon vascular injury in mouse carotid arteries [104]. The loss of KLF4 has favorable
effects, inhibiting plaque pathogenesis and reducing plaque vulnerability [106]. KLF4 is critical in
the regulation of phenotypic switching of VSMCs, both in vitro and in vascular injury models. KLF4
expression results in profound activation of pluripotency genes such as Oct4 and Sox2, indicating that
VSMCs can reactivate its pluripotency network in response to vascular stress or damage [5]. Moreover,
KLF4 activates > 800 pro-inflammatory VSMC genes, of which many are atherosclerosis relevant [106].
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Additionally, KLF4 knock-out in an atherosclerosis animal model revealed the switch of VSMCs toward
a synthetic phenotype, while suppressing the macrophage-like form [106].
3. Clinical Features of Vascular Remodeling
3.1. Hypertension
Hypertension is widely accepted as a risk factor for the development of CVD. However,
hypertension was first considered to be a consequence of aging and seen as insurmountable [107].
Later, several studies revealed that hypertension was associated with increased cardiovascular
mortality [108,109]. A meta-analysis on blood pressure and cardiovascular disease showed that a rise
of 20 mmHg in systolic blood pressure (SBP) and of 10 mmHg in diastolic blood pressure (DBP) was
associated with a more than two-fold increase in vascular mortality [110]. More recently, the CALIBER
study revealed that patients with hypertension (defined as > 140/90 mm Hg or those receiving blood
pressure-lowering drugs) have a lifetime risk for overall CVD of 63.3% at 30 years of age (compared to
46.1% in patients with normal blood pressure) and develop CVD 5 years earlier [111]. Decreasing the
SBP by 20 mmHg was associated with a 39% reduction in cardiovascular (CV) events in the total group
and in a 69% reduction in patients between 60 and 69 years of age [112]. Currently, much of the focus
on the primary and secondary prevention of CVD revolves around control of blood pressure [112].
The systolic aspect of hypertension is quite strongly determined by age- and disease-related
decreases in arterial compliance [9,111–113]. Therefore, arterial remodeling processes affecting medial
elastic properties are directly relevant in risk profiling and as treatment targets.
3.1.1. Cellular Components and Hypertension
High blood pressure is a multifactorial disorder in which genetic alterations, environmental factors
and comorbidities interact [24,114]. ECs play an important role in the development of hypertension.
In health, ECs are exposed to physiological shear stress, which is necessary to maintain proper
functioning of the endothelium. The NO excreted by ECs regulates vascular tone, and thereby
preserves ECM and VSMCs’ functioning [115]. In pathology, blood flow is more oscillatory, with higher
peaks and blood stasis during diastole [116]. Turbulent flow and changes in shear stress, either high or
low, affect EC function. Low shear stress areas are considered prone to developing atherosclerosis,
inducing pro-inflammatory pathways and lead to dysregulation of the cytoskeleton and junctional
proteins of ECs [115,117,118]. High shear stress induces morphological changes in ECs, as they align
in the direction of the flow. Additionally, arterial outward remodeling occurs, leading to increased NO
synthesis [119,120].
In hypertension, the amplitude and rate of elastic distension of arteries are increased, causing
fatigue, damage and degradation of the vessel wall ECM [32]. Moreover, excessive VSMC strains
induce phenotypic switching of these VSMCs to more synthetic types and, consequently, promotes
arterial fibrosis, (further) compromising arterial compliance [121].
3.1.2. Calcification and Hypertension
Several pathologies are associated with VSMC phenotype switching [12]. Synthetic VSMCs
produce EVs [2,122,123], that have been found in both the intimal and medial layers of the vessel
wall [124]. VSMCs are known to release EVs upon phenotypic switching towards synthetic or
osteogenic phenotype. EVs derived from VSMCs share similarities with EVs from osteoblasts, having
calcium-binding capacities and osteoblast-like ECM production [2,80]. Recently, it was shown that
not all EVs promote calcification [125]. This implies that EV content is variable and dependent on
VSMC-mediated biogenesis. A specific subclass of EVs are exosomes, which express tetraspanins (CD9,
CD63 and CD81) and differ in expression pattern, and, hence, mineralizing capacity [125]. Furthermore,
calcifying conditions in vitro increase the multi-vesicular body, forming enzyme sphingomyelin
phosphodiesterase 3 (SMPD3) and subsequent exosome genesis [80]. Consequently, the inhibition of
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SMPD3 ablates the generation of exosomes and their subsequent calcification. Additionally, sortilin
has been suggested as a key player in the VSMC-mediated calcifying EVs genesis and release. Sortilin
is a sorting receptor that directs target proteins to a designated location via the secretory or endocytic
compartment [126]. Recent findings have identified that sortilin promotes vascular calcification via the
trafficking and loading of tissue-nonspecific alkaline phosphatase into EVs [127]. Moreover, sortilin
co-localized with calcification in human calcified vessels [127]. Differences between mineralizing and
non-mineralizing EVs eventually determine calcification of the ECM in proximity of VSMCs. Hence,
better insight into EV composition, such as lipid content and RNA and protein profile, might provide
new insights into the mechanism by which VSMC derived EVs contribute to vascular calcification and
result in novel targets for treatment.
In response to calcified ECM, neighboring ECs and VSMCs react and induce the production of
osteogenic factors, such as bone morphogenetic protein 2 (BMP-2) and 4 (BMP-4) [128,129]. Besides this
expression of bone-associated proteins, the number of VSMCs decreases with age, and an increase of
collagen-to-elastin ratio further increases the stiffening of the vessel wall [130].
In hypertension, calcium handling is disturbed, which is associated with an increased activation of
L-type calcium channels and sensitivity of (hypertensive) patients toward calcium channel blockers [131].
Increased intracellular calcium induces the activation of receptors coupled to phospholipase C, leading
to the generation of second messengers that trigger cytokines, ROS and miRNAs, and also cellular
derived EVs [132,133]. Additionally, increased intracellular calcium activates the contractile machinery
of VSMCs, leading to hyper-contractility. Excessive intracellular calcium rapidly disintegrates both
mitochondria and structural components of VSMCs, and results in calcium depositions within
elastic fibers [130]. Consequently, elasticity of the vasculature decreases, further contributing to
increased blood pressure [24,134] and VSMC stiffening [135,136]. Specific calcium antagonists,
blocking L-type voltage-dependent calcium channels, reduce calcium internalization and normalize
blood pressure [137–139]. Of note, these calcium channel blockers also prevent calcification of the
vasculature [140].
3.1.3. Consequences of Vascular Calcification
Vascular calcification is associated with arterial stiffness [32,141]. In chronic kidney disease,
medial calcification of large arteries is directly responsible for the increased stiffness (or reduced
distensibility) [142,143]. The presence of vascular calcification (process) in the vessel wall contributes
to ECM degradation and wall thickening [49,144]. Taken together, vascular calcification contributes
directly and indirectly to arterial stiffening and, ultimately, hypertension [145,146]. Atherosclerosis
has also been associated with arterial stiffness and hypertension [147,148]. Additionally, increased
blood pressure and wall shear stress increase vulnerability and, consequently, atherosclerotic plaques
become prone to rupture [30,149].
3.2. Atherosclerosis
Atherosclerosis is characterized by intimal plaque build-up and often referred to as a thickening
of the vessel wall, ultimately narrowing the lumen of the vessel. Atherosclerosis is considered an
inflammatory disease, starting with endothelial stress and subsequent monocyte infiltration [150,151].
Clinically, plaques may rupture, resulting in stroke or myocardial infarction [104]. Besides the classical
view that systemic factors are causative for atherosclerosis, recent data suggest that local vascular
processes also initiate atherogenesis [104]. Lineage tracing studies revealed that many of the cells
present in atherosclerotic plaques are derived from VSMC precursors [30]. Additionally, it is now
recognized that atherosclerotic plaque macrophages have lineage traces of VSMCs, indicating that cells
in the intima originate from the vascular media, and not necessarily from the circulating mesenchymal
cells that infiltrate the vessel wall at sites of injury [152].
Arterial remodeling is considered key to the development of atherosclerosis [148,153].
Arterial remodeling of the vessel wall can be initiated via many processes, including oxidative
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stress [2], proliferation [58], VSMC phenotype switching [154], cell infiltration, apoptosis and
calcification [155–157].
3.3. Intimal and Medial Aspects of Vascular Calcification
Vascular calcification can be found at two anatomical locations, the medial and intimal layer.
In the 1940s, post-mortem analysis of aortic specimens from CVD patients revealed that atherosclerosis
is only present at vascular areas with either medial degradation or medial calcification [158–161].
Histological examination of aortas showed that medial calcification preceded atherosclerotic plaque
build-up. Intimal calcification is seen as a hallmark of atherosclerosis and, clinically, is used as
a marker for atherosclerotic burden [162]. For a long time, calcification has been considered as a
passive degenerative detrimental process, not amendable for intervention. This view has recently
changed, since statin treatment is associated with both increased plaque stability and increased plaque
calcification [163–165]. However, the apparent protective role of calcification in stabilizing plaque is in
contrast with the predictive value of calcification for CVD morbidity and mortality [160,164]. Moreover,
medial calcification has been shown to change blood dynamics by inducing arterial remodeling
processes and increasing arterial stiffness [166–168]. Medial calcification strongly correlates with
the phenotypical switching of VSMCs and a rise in blood pressure. Macrocalcifications in patients
who underwent a computed tomography (CT) scan were shown to have a three- to four-fold risk of
developing fatal cardiovascular events [169]. Additionally, microcalcifications, which are precursors of
macrocalcification, have been shown to induce plaque vulnerability [170].
Cellular Processes of Vascular Calcification
Specific stimuli, such as elevated calcium or phosphate levels, induce the switching of VSMCs to an
osteogenic phenotypic where the cells acquire features of chondrocytes and osteoblasts [24]. Osteogenic
VSMCs show an increased expression of osteogenic markers, such as alkaline phosphatase, BMP-2
and runt-related transcription factor 2 (Runx2), but show decreased calcification-inhibitor protein
expression [171]. VSMCs exposed to elevated calcium levels display an intracellular calcium overload
that may induce microcalcifications, eventually resulting in macrocalcification, which contributes
to vascular stiffness and hypertension [172]. The process of calcification, culminating in either
micro- or macrocalcification, compromises the structural integrity of the vessel wall and, hence,
its functional properties.
Oxidative stress is an important player in the development of vascular calcification. Oxidative
stress pathways in VSMCs have been linked to development aortic valve calcification [173]. Increased
oxidative stress induces expression of Runx2, a key transcription factor associated with osteoblast
differentiation [174]. VSMC-specific Runx2 knockout was shown to decrease vascular calcification
and atherosclerosis development [175]. Additionally, increased H2O2 levels have been found in the
close vicinity of calcification nucleation foci, together with an enhanced expression of oxidases [173].
High phosphate levels, present in chronic kidney disease, are associated with extent of vascular
calcification [176]. In vitro, phosphate has been shown to induce mitochondrial-derived free radicals,
by enhancing mitochondrial membrane potential [177]. Antioxidants inhibit phosphate-induced ROS
production [177]. Increased oxidative stress is also found in diabetic patients [178], leading to an
increased accumulation of advanced glycation end products (AGEs). AGEs have been shown to induce
vascular calcification via increased oxidative stress of VSMC [179,180].
3.4. Fibrosis
Fibrosis of different organs contributes to up to 50% of worldwide mortality [181,182]. In the
vasculature, myofibroblasts produce ECM proteins such as collagen and fibronectin [12]. Myofibroblasts
are derived from MSC-like cells that reside in the vessel wall. The role of these MSC-like cells in
the vessel wall is not fully understood, and is believed to play an important role in structural
vessel repair. In vascular fibrosis, excessive collagen deposition leads to a reduced compliance of
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the vessel, which indicates increased arterial stiffness. Furthermore, high blood pressure induces
structural changes including hypertrophy of the vessel wall [183,184] and cellular [185] and ECM
remodeling [186].
Lineage tracing studies have shown that resident Gli1+ MSC-like cells are a major contributor
of vascular fibrosis in arterial remodeling [187]. Acute vessel wall injury revealed that a significant
number of Gli1+ cells were detected in the media and neointima, and that they express VSMC markers
such as αSMA and CNN1. Additionally, some 50% of the newly formed VSMCs were derived
from Gli+ progenitors, indicating the involvement of adventitial cells in arterial remodeling [188].
Likewise, angiotensin II induced hypertension was caused by an exuberant production of collagen
in the adventitial layer [189]. VSMCs that migrate towards the adventitia start expressing stem cell
markers Sca-1 and CD34 [186]. These “adventitial stem cells” change towards fibroblasts and deposit
collagen and other ECM, contributing to adventitial fibrosis [190,191].
During atherosclerosis development, fate-tracing studies in mice have shown that MSC-like
cells migrate into the media and neo-intima. Also, MSC-like Gli1+ cells were a major source
of osteoblasts-like cells, significantly contributing to the process of vascular calcification in both
vascular media and intima. The genetic ablation of Gli+ cells before injury dramatically reduced the
severity of vascular calcification [192]. These data indicate that fibrotic processes are regulated by
myofibroblasts and MSC-like cells and that these are important in the development of atherosclerosis
and vascular calcification.
4. Assessing Vascular Remodeling and Disease
4.1. Pulse Wave Velocity (PWV), Distensibility Coefficient (DC) and Intima-Media Thickness (IMT)
Carotid-femoral PWV is considered the gold standard for assessing central arterial
stiffness [193,194]. PWV, however, only measures vascular characteristics of the aorta and does
not harbor information on any other vessels. Multi-slice CT, measuring calcification, reflects the
atherosclerotic burden, and IMT measures atherosclerosis in the carotid arteries. Below, we describe in
more detail measures of vascular remodeling and disease.
4.1.1. Pulse Wave Velocity
Measuring arterial stiffness in the clinic is challenging. The methods that are available for
measuring arterial stiffness are non-invasive vascular imaging, such as ultrasound and magnetic
resonance imaging (MRI), and high-fidelity recording of the pulse wave, performed by tonometry
or ultrasound Doppler. Functional measures that can be obtained are pulse wave velocity (PWV)
and the distensibility coefficient (DC). In the clinic, carotid–femoral PWV (cfPWV) adds to existing
risk scores in cardiovascular risk management [195], while arterial stiffening has been shown to be
independently associated with cardiovascular risk and mortality [16]. Brachial-ankle PWV is also used
as an alternative to cfPWV, correlating reasonably well [16].
The interpretation of arterial stiffness findings in human studies is subject to (1) the stiffness
measure/method used and (2) the mechanistic or constitutive focus of the study. Constitutive properties
that are often considered to interpret arterial stiffness findings are those related to the ECM or
VSMCs [196,197].
4.1.2. Distensibility Coefficient
Arterial stiffness can be determined by measuring local vessel diameter and distension by
ultrasound or MRI [198]. The measured data can be used to calculate the local distensibility coefficient
(DC) or compliance. PWV, as well as DC, are well known to be pressure dependent and require
blood pressure adjustment [199]. Adjustment is valid when considering group analyses, but lacks
applicability in the use of individual cases [32,200].
Int. J. Mol. Sci. 2019, 20, 5694 13 of 29
PWV is largely dependent on the elastic properties of the large arteries. Therefore, PWV should
be interpreted with care, since it only reflects the stiffness of the aorta. In conduit arteries, the relative
amount of VSMCs are limited and, thus, the contribution of ECM to arterial stiffening may be expected
to be more pronounced. In peripheral, more muscular, arteries, age-related stiffening is not as
straightforward [201,202]. PWV in the lower extremities can change significantly, which may explain
why no evident relation between PWV and age has been reported [203]. Additionally, hypertrophy
of VSMCs is commonly observed in hypertension [204], with the potential to (partially) determine
PWV [205]. Thus, PWV is an important clinical marker for risk assessment, as it correlates with
cardiovascular risk, mortality, and organ damage of the heart, kidney and brains [206,207].
Techniques for measuring PWV are developing. cfPWV is most commonly used for aortic
stiffness, but is susceptible to local wave reflections and not suitable for obtaining information
on carotid arteries [208]. Ultrasound ultrafast imaging techniques are being explored to directly
measure the propagation of the pulse wave, with limited success for the common carotid artery [209].
Elastography is a promising technique, as it measures the propagation of shear waves in the tissue [210].
The propagation of the shear wave is directly proportional to the elastic modulus of the tissue [16].
PWV can also be measured using MRI, which also allows for segmentation. Its drawbacks are costs
and long scanning times [33]. Currently, the available PWV toolbox can only be applied to large and
medium-sized arteries, but techniques are developing for smaller vessels.
At present, the interpretation of stiffness measurements in terms of arterial wall constitutive
properties remains a challenge [187]. Medial calcifications are known to co-localize with elastin
fragmentation spots, but the mechanical contribution of the calcific deposits to vessel stiffness remains
to be established; the elastin degradation alone could be sufficient to explain stiffening [211].
4.1.3. Intima-Media Thickness
IMT is used as a measurement for assessing the thickness of the tunica intima and media
(estimated from lumen-intima and media-adventitia echo complexes). IMT is often measured using
ultrasound and can be readily obtained in superficial arteries. One aspect that is not measured by IMT
is adventitial thickness is a significant contributor of pathology development [212]. Wall thickness
data are important in determining arterial wall material stiffness and wall stress. But, IMT can also
be used to detect atherosclerosis, and is used to follow progression of the disease [213,214]. IMT is
shown to be an independent predictor of overall cardiovascular events, including myocardial infarction
and stroke [215]. Multiple studies have shown that increases in IMT can be significantly delayed
using effective cardiovascular drugs, such as statins [216,217]. However, further observational studies
revealed that this delay did not result in reduced cardiovascular events [218].
To study large populations, non-invasive techniques such as IMT are preferred over invasive
measurement tools. As such, IMT provides a reliable tool for assessing vessel wall macro-structural
changes. However, some limitations for IMTs exist. There is a lack of standardized protocols for the
use of IMT, and attempts to establish them have not reached consensus yet [219]. IMTs of certain
segments, such as the common carotid artery, are related to hypertension, blood pressure and vascular
hypertrophy [220], whereas the internal carotid artery correlates with atherosclerotic plaques [221,222].
Taken together, additional risk assessments, such as plaque presence and stenosis severity, will be
complementary to the use of IMT alone. A novel technique to determine extra-media thickness may
have great potential in combination with IMT to discriminate between the medial and adventitial layer
which aids in risk assessment [223,224]. Moreover, other imaging techniques, such as coronary artery
calcium (CAC) scanning, have been demonstrated to be superior for predicting CVD events [155,225].
4.2. Calcification Imaging by Computed Tomography
Calcification imaging in the clinic is mostly based on CT, which is an angiography technique based
on X-ray radiation and makes use of computer processing to create a detailed 3D image. Calcification
scores, such as the coronary artery calcium (CAC) score, can be derived from CT scans and, in recent
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decades, this has been used as a measure of atherosclerotic burden. The Agatson score is the most
frequently used method to calculate CAC. The Agatston score is defined as a weighed sum of the
calcification area, with density given as Hounsfield Units [226]. CAC represents an accurate measure
to assess atherosclerotic burden [227,228]. Additionally, CAC correlates with traditional risk factors
for atherosclerosis, such as hypertension, hypercholesterolemia and diabetes [227,228]. CAC also
associates with cardiovascular morbidities and mortalities, including cardiac death and stroke [229].
CAC is regarded as the best clinical predictor for the accumulation and progression of vascular
calcification over time [230–232]. CAC can be used to identify high-risk individuals that need immediate
medical attention or intervention [233]. Interventions to slow down or even regress calcification,
using the supplementation of vitamin K, are currently being conducted [234]. High dietary intake of
vitamin K is associated with a lower risk of coronary heart disease [235–237] and supplementation
with vitamin K significantly delays the progression of calcification [238]. Conversely, statin treatment
is known for its beneficial cardiovascular effects, however, it is also shown to increase CAC score [239].
This indicates that type of calcification, as well as the volume or density of calcification, determines
whether it is plaque-stabilizing or plaque-destabilizing. Indeed, CAC volume is positively and
independently associated with CVD, whereas CAC density was inversely correlated with CVD
risk [240].
Measuring CAC as a clinical marker for CVD has some limitations. Firstly, CAC is limited
to coronary arteries, which do not represent the calcification of other vessels of the arterial system.
CAC does not represent total plaque size, as histopathological studies showed that the area of
calcium deposition was much smaller than total plaque volume [241,242]. Additionally, CAC score
poorly correlated with luminal narrowing and severity [217,243,244]. Secondly, distinction between
medial and intimal calcification is not possible with current resolutions of CT. Intimal and medial
calcification are different pathologies, with different risk factors for developing CVD [245]. Additionally,
microcalcification (< 15 µm) cannot be assessed, as the resolution of CT is some 200 µm [246].
Thirdly, evidence suggests that atherosclerotic plaques that have denser calcification have smaller
lipid cores, with increased stability of plaques, resulting in lower CVD risk [247]. Greater CAC
volume, however, is associated with a higher risk of CVD [248]. This indicates that future research
should integrate density and volume into CAC scoring. Finally, CAC involves exposure to radiation,
which limits the use of calcium scores as a follow-up on atherosclerosis progression [249].
4.3. 18F-NaF Positron Emission Tomography
18F-NaF PET scanning gained recent attention as a novel imaging modality for vascular
calcification [250]. In bone, 18F-NaF is incorporated into newly formed hydroxyapatite crystals
by exchanging fluoride with the hydroxyl groups [251]. In the vasculature, 18F-NaF PET imaging has
been reported to identify active (micro)calcification with high specificity [252]. Importantly, CT and
echocardiography cannot identify active vascular calcification, which is considered the main driver
of disease progression [253]. Assessing the molecular bioactivity of calcification in atherosclerotic
plaques is of additive value to identify vulnerable plaques [254,255]. Additionally, ex vivo histological
studies showed that the resolution of 18F-NaF has the potential to discriminate between micro-and
macrocalcification [254]. Taken together, 18F-NaF uptake provides complementary information to CT,
as it allows for the detection of ongoing active calcification of plaques, which is a major improvement to
the prediction of future cardiovascular risk. Limitations of 18F-NaF PET imaging are the relatively high
costs and exposure to radiation, but, also, 18F-NaF PET imaging lacks the resolution to discriminate
between medial and intimal calcification.
5. Conclusions
Arterial remodeling is defined as the adaptation of the vessel wall away from a normal homeostatic
state towards pathologic development, triggered by chronic exposure to stress signals. Different arterial
remodeling processes have been described, such as inflammation, oxidative stress, lipid accumulation,
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and degradation of the ECM. Many of these are regulated by VSMCs and affect vessel wall morphology
and properties. VSMCs exhibit cellular plasticity and, upon stress stimuli, they may differentiate
towards synthetic, macrophage-like and osteogenic VSMCs. As a consequence, VSMCs initiate
and support remodeling processes involving ECM synthesis and cell proliferation, migration and
contraction, which aid in maintaining tissue functionality. Disruption of VSMC phenotypic plasticity
has many pathological consequences, including the development of hypertension, atherosclerosis,
aneurysm formation, intimal and medial calcification, and vascular fibrosis, ultimately leading
to increased CVD morbidity and mortality. Early detection of vascular remodeling is key in the
prevention and prognosis of CVD. Clinically, assessment of calcification-mediated remodeling remains
difficult. Assessment tools include measurements of pulse wave velocity, distensibility coefficient and
intima-media thickness. These techniques may capture changes in dynamic and geometric vessel wall
properties, but cannot directly monitor the underlying arterial remodeling processes. The addition
of techniques, such as 18F-NaF PET and CT imaging may provide further mechanistic insight into
vascular calcification development and other VSMC-mediated processes.
Combining expertise in vascular biology, clinical vascular expertise and multi-scale/multi-modality
imaging should advance the understanding and identification of critical determinants of vascular
remodeling, ultimately resulting in tailor-made diagnoses and treatments.
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Abbreviations
α-SMA alpha-smooth muscle actin
AGE advanced glycation end product
BMP-2 bone morphogenetic protein 2
BMP-4 bone morphogenetic protein 4
CAC coronary artery calcium
CD9 cluster of differentiation 9
CD34 cluster of differentiation 34
CD63 cluster of differentiation 63
CD81 cluster of differentiation 81











IL-1β interleukin 1 beta
IMT intima-media thickness
KLF4 kruppel-like factor 4
MMP metalloproteinase
MRI magnetic resonance imaging
MSC mesenchymal stem cell
MYC11 smooth muscle-myosin heavy chain
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NAD(P)H nitrate reductase
NO nitric oxide
Oct4 octamer-binding transcription factor 4
p16INK4a cyclin-dependent kinase inhibitor 2A
p21 cyclin-dependent kinase inhibitor 1
PAR protease activated receptor
PF4 platelet factor 4
PDGF platelet derived growth factor
PXE pseudoxanthoma elasicum
PWV pulse wave velocity
ROS reactive oxygen species
Runx2 runt-related transcription factor 2
SBP systolic blood pressure
Sca-1 Spinocerebellaire ataxie type 1
SM22-α smooth muscle 22-alpha
SMPD3 sphingomyelin phosphodiesterase 3
smtn Smoothelin
VSMC vascular smooth muscle cell
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